Skip to content
Pfizer
-
Pfizer ends Danuglipron development after liver injury in trial
Danuglipron belongs to a class of drugs targeting the GLP-1 hormone, which plays a role in appetite regulation and weight management.
-
Pfizer completes Haleon exit with US$3.3B sale
This strategic decision is part of Pfizer’s broader effort to streamline its operations and focus on high-growth areas such as oncology and rare diseases.
-
-
-
-
-
-
-
-
